AR006202A1 - Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene - Google Patents
Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contieneInfo
- Publication number
- AR006202A1 AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- treatment
- ige
- ige antagonist
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Usos y composiciones de antagonista IgE para preparar un medicamento útil para el tratamiento de una enfermedad alérgica caracterizado por una cantidadefectiva de dicho antagonista IgE, que es administrado como: (a) una dosis de carga durante unperíodo de al menos alrededor de 14 días suficientes parareducir el nivel promedio de IgE libre en suero del paciente hasta un nivel no mayor de alrededor de 50ng/ml al final del período de carga; seguido por (b)una dosis de mantenimiento entrealre dedor de 8x10(5) hasta 2.4x10(3) mg/kg/semana del antagonista IgE para cada IU/ml línea de base IgE libre en elsuero del paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61422096A | 1996-03-12 | 1996-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR006202A1 true AR006202A1 (es) | 1999-08-11 |
Family
ID=24460327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100986A AR006202A1 (es) | 1996-03-12 | 1997-03-12 | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0904108A1 (es) |
JP (1) | JP2001505181A (es) |
AR (1) | AR006202A1 (es) |
AU (1) | AU726143B2 (es) |
CA (1) | CA2246427A1 (es) |
IL (1) | IL126113A0 (es) |
WO (1) | WO1997033616A1 (es) |
ZA (1) | ZA971607B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US7393529B2 (en) | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
AU2065801A (en) * | 1999-12-06 | 2001-06-12 | Panacea Pharmaceuticals, Llc | Passive desensitization |
GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
AU2002316887A1 (en) * | 2001-05-03 | 2002-11-18 | Novartis Ag | Anti-ige antibody to treat ocular allergies |
GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CN114028569B (zh) * | 2021-12-20 | 2023-04-28 | 中国医学科学院基础医学研究所 | 免疫球蛋白IgE在诊断和/或治疗高血压中的用途 |
CN114504644B (zh) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | 抗IgE抗体在用于治疗腺样体肥大中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US4940715A (en) * | 1988-05-17 | 1990-07-10 | Kissei Pharmaceutical Co., Ltd. | 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities |
JP3156237B2 (ja) * | 1991-12-24 | 2001-04-16 | 雪印乳業株式会社 | 抗ヒトIgE モノクローナル抗体 |
-
1997
- 1997-02-25 ZA ZA971607A patent/ZA971607B/xx unknown
- 1997-03-06 AU AU19875/97A patent/AU726143B2/en not_active Ceased
- 1997-03-06 CA CA002246427A patent/CA2246427A1/en not_active Abandoned
- 1997-03-06 IL IL12611397A patent/IL126113A0/xx unknown
- 1997-03-06 WO PCT/US1997/003443 patent/WO1997033616A1/en not_active Application Discontinuation
- 1997-03-06 EP EP97908025A patent/EP0904108A1/en not_active Withdrawn
- 1997-03-06 JP JP53267597A patent/JP2001505181A/ja active Pending
- 1997-03-12 AR ARP970100986A patent/AR006202A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2246427A1 (en) | 1997-09-18 |
IL126113A0 (en) | 1999-05-09 |
AU726143B2 (en) | 2000-11-02 |
JP2001505181A (ja) | 2001-04-17 |
ZA971607B (en) | 1998-08-25 |
AU1987597A (en) | 1997-10-01 |
EP0904108A1 (en) | 1999-03-31 |
WO1997033616A1 (en) | 1997-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69027216D1 (de) | Transmukosale dosisform | |
KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
ES2171469T3 (es) | Composicion administrada por via nasal y preparacion que la contiene. | |
PT88985A (pt) | Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina | |
DE69230112T2 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
ATE94393T1 (de) | Dosisform zur oralen verabreichung des hypoglykaemischen glipizids. | |
KR101900520B1 (ko) | 복합 조성물 | |
ATE92762T1 (de) | Medikamente. | |
MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
Ryan et al. | Experiences in the treatment of Paget's disease of bone with mithramycin | |
NZ225242A (en) | Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs | |
DK0412554T3 (da) | Sustained-release-præparat til administration i hjernen | |
ES2139842T3 (es) | Uso de la melatonina para tratar a pacientes que sufren drogodependencia. | |
AR006202A1 (es) | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene | |
RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
ES2119748T3 (es) | Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. | |
KR890006227A (ko) | 페놀-함유 진해성 액체 조성물 | |
ES2115571T3 (es) | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. | |
JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
KR890004705A (ko) | 항바이러스성 제제 | |
JPS6360940A (ja) | 白内障の予防または治療剤 | |
AR002727A1 (es) | El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion. | |
ES2038847T3 (es) | Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines. | |
ES2211594T3 (es) | Medicamentos que contienen acido pantotenico para el tratamiento de enfermedades inflamatorias de las articulaciones. | |
EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique |